[{"id":"0db89e9b-db2b-43cc-83d7-77deb9d111cd","acronym":"SCOUT","url":"https://clinicaltrials.gov/study/NCT02637687","created_at":"2021-01-17T17:20:37.992Z","updated_at":"2025-02-25T12:26:24.234Z","phase":"Phase 1/2","brief_title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","source_id_and_acronym":"NCT02637687 - SCOUT","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-24"},{"id":"a1cc20b7-e120-4c96-ad2e-1583010cd20c","acronym":"CARE study","url":"https://clinicaltrials.gov/study/NCT04094610","created_at":"2021-01-18T20:02:04.781Z","updated_at":"2025-02-25T14:40:19.057Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","source_id_and_acronym":"NCT04094610 - CARE study","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-14"},{"id":"277136d1-0119-42be-9629-e04f1cfca67d","acronym":"TRIDENT-1","url":"https://clinicaltrials.gov/study/NCT03093116","created_at":"2021-01-17T17:11:31.349Z","updated_at":"2025-02-25T16:31:09.380Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","source_id_and_acronym":"NCT03093116 - TRIDENT-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-07"},{"id":"2b6e1463-c371-4b17-a2c1-81d56ff0988e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03215511","created_at":"2021-01-18T15:52:01.409Z","updated_at":"2025-02-25T17:09:49.126Z","phase":"Phase 1","brief_title":"A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer","source_id_and_acronym":"NCT03215511","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e selitrectinib (BAY 2731954)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 07/03/2017","start_date":" 07/03/2017","primary_txt":" Primary completion: 04/11/2022","primary_completion_date":" 04/11/2022","study_txt":" Completion: 01/30/2023","study_completion_date":" 01/30/2023","last_update_posted":"2024-10-30"},{"id":"41b01b41-ccaf-44d0-9901-ee4360f0dfd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828303","created_at":"2023-04-25T14:03:37.911Z","updated_at":"2024-07-02T16:35:10.118Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05828303","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-04-11"},{"id":"1cdd60d2-369d-4e42-890d-606bbb974c28","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010342","created_at":"2023-08-24T16:11:42.524Z","updated_at":"2024-07-02T16:35:10.443Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","source_id_and_acronym":"NCT06010342","lead_sponsor":"Teligene US","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TL118"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-10"},{"id":"a005015e-d5d3-4c57-83b2-3093dd60eeae","acronym":"TOTEM","url":"https://clinicaltrials.gov/study/NCT04772235","created_at":"2021-02-26T13:55:19.583Z","updated_at":"2025-02-25T14:29:55.997Z","phase":"Phase 1","brief_title":"Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients","source_id_and_acronym":"NCT04772235 - TOTEM","lead_sponsor":"Instituto Oncológico Dr Rosell","biomarkers":" ALK • MET • ROS1 • HAVCR2 • NTRK","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR T790M","tags":["ALK • MET • ROS1 • HAVCR2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/11/2022","start_date":" 02/11/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-03"},{"id":"b0bd248a-bd03-4ed3-b6a6-a8c5210d9df6","acronym":"REPOSE","url":"https://clinicaltrials.gov/study/NCT06315010","created_at":"2024-03-18T15:22:57.128Z","updated_at":"2024-07-02T16:35:14.368Z","phase":"Phase 2","brief_title":"REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis","source_id_and_acronym":"NCT06315010 - REPOSE","lead_sponsor":"MedSIR","biomarkers":" ROS1","pipe":"","alterations":" ","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-03-18"},{"id":"78482e2a-4e36-4c51-a81b-de4897029fc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05004116","created_at":"2021-08-13T12:53:24.897Z","updated_at":"2024-07-02T16:35:15.181Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer","source_id_and_acronym":"NCT05004116","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-03-12"},{"id":"ad35a256-b12d-4264-8406-c8f148399527","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828277","created_at":"2023-04-25T14:03:37.480Z","updated_at":"2024-07-02T16:35:35.756Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients","source_id_and_acronym":"NCT05828277","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2 • AFP • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2 • AFP • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2022","start_date":" 07/28/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-26"},{"id":"d0232ee2-cfb8-4d08-8138-198a58818661","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769075","created_at":"2023-03-15T14:02:16.876Z","updated_at":"2024-07-02T16:35:49.864Z","phase":"Phase 1","brief_title":"A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations","source_id_and_acronym":"NCT05769075","lead_sponsor":"TYK Medicines, Inc","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • ALK rearrangement • ALK fusion • ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • ALK rearrangement • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TY-2136b"],"overall_status":"Recruiting","enrollment":" Enrollment 282","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-04-24"},{"id":"08544267-425c-42aa-87ee-a72f61d133e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04614740","created_at":"2021-02-22T08:58:34.782Z","updated_at":"2024-07-02T16:35:59.178Z","phase":"Phase 2","brief_title":"The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT04614740","lead_sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VC004"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-12-13"},{"id":"f940d82e-06f2-44db-8afc-37bc80ceac97","acronym":"","url":"https://clinicaltrials.gov/study/NCT04996121","created_at":"2021-08-09T13:53:04.483Z","updated_at":"2025-02-25T17:11:55.305Z","phase":"Phase 1/2","brief_title":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04996121","lead_sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","biomarkers":" ROS1 • NTRK","pipe":" | ","alterations":" ROS1 fusion • ROS1 positive • NTRK fusion","tags":["ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion • ROS1 positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XZP-5955"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2022-08-30"},{"id":"38586fe8-a3bb-493e-ab3e-daaa8e0d3984","acronym":"","url":"https://clinicaltrials.gov/study/NCT05212987","created_at":"2022-01-29T18:05:39.593Z","updated_at":"2024-07-02T16:36:17.854Z","phase":"Phase 1","brief_title":"Study of FCN-098 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05212987","lead_sponsor":"Fochon Pharmaceuticals, Ltd.","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FCN-098"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 05/08/2024","primary_completion_date":" 05/08/2024","study_txt":" Completion: 10/12/2024","study_completion_date":" 10/12/2024","last_update_posted":"2022-01-28"},{"id":"25c64f33-801c-46c5-8cbf-381cc597fe7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206931","created_at":"2021-01-18T15:48:28.443Z","updated_at":"2025-02-25T17:09:47.148Z","phase":"","brief_title":"Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion","source_id_and_acronym":"NCT03206931","lead_sponsor":"Bayer","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e selitrectinib (BAY 2731954)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-09-16"},{"id":"2f8a0b9b-5eb1-43c3-93e2-5b9c6b8ed148","acronym":"","url":"https://clinicaltrials.gov/study/NCT02048488","created_at":"2021-01-18T09:24:44.946Z","updated_at":"2024-07-02T16:37:01.267Z","phase":"Phase 1/2","brief_title":"A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas","source_id_and_acronym":"NCT02048488","lead_sponsor":"Tesaro, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e belizatinib (TSR-011)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2019-03-26"}]